Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
AssigneeExocell, Inc.
InventorMargo P. Cohen
Life of this patent
Estimating the term…
Abstract
Methods of in vivo diagnosis and treatment for complications of diabetes are provided. Antibodies or other mimetic molecules which specifically bind to glycated albumin or its cellular receptor are administered to a human. Glycated albumin which retains a deoxyfructosyllysine moiety is found deposited at sites of diabetic tissue damage. Glycated albumin inhibits the growth of cells. Treatment with monoclonal anti-glycated albumin antibody reverses the growth inhibition caused by glycated albumin. In addition, glycated albumin stimulates the production of type IV collagen by kidney cells. Antibodies which bind to glycated albumin prevent the stimulation of type IV collagen production.
Claims9
A method of treating complications of diabetes which are caused by glycated albumin, comprising the steps of:
- parenterally administering to a diabetic patient a therapeutic molecule which specifically binds the glycated albumin epitope bound by the monoclonal antibody produced by cell line ATCC HB 9596.
Dependencies are inferred from the claim text.